%0 Figure %A P. Williams, Justin %A Kim, Inki %A Ito, Emma %A Shi, Wei %A Yue, Shijun %A L. Siu, Lillian %A Waldron, John %A O'Sullivan, Brian %A W. Yip, Kenneth %A Liu, Fei-Fei %D 2014 %T Dacomitinib demonstrated in vitro efficacy in EGFR over-expressing SCCHN cell lines. %U https://plos.figshare.com/articles/figure/_Dacomitinib_demonstrated_in_vitro_efficacy_in_EGFR_over_expressing_SCCHN_cell_lines_/1034699 %R 10.1371/journal.pone.0098557.g002 %2 https://ndownloader.figshare.com/files/1508331 %K physiology %K Endocrine physiology %K Growth factors %K Epidermal growth factor %K oncology %K Cancers and neoplasms %K carcinomas %K Squamous cell carcinomas %K Head and neck squamous cell carcinoma %K Head and neck tumors %K Cancer treatment %K Radiation therapy %K demonstrated %K efficacy %K egfr %K over-expressing %K scchn %X

(A to D) Growth inhibition of three SCCHN and the NOE cell lines, treated with Dacomitinib, with or without IR. (B) FaDu; (C) UT-SCC-8; (D) UT-SCC-42a; and (E) NOE cells were treated with Dacomitinib (0, 10, 25, 50, 100, or 250 nM) alone, or in combination with IR (0, 2, or 4 Gy). MTS assays were conducted 72 hours post-treatment. The graphs represent data from 3 independent experiments, with the mean ± SEM reported. *p<0.05, **p<0.01, ***p<0.001; one-way ANOVA. No statistically significant difference between curves for Figure 2A-D; two-way ANOVA. Combination of Dacomitinib plus RT did not result in a synergistic interaction for any of the dosing regimens in all three SCCHN cell lines (Chou-Talalay Method).

%I PLOS ONE